Recent Finacing
Recent Raise
Nuvalent is a Cambridge-based biotech developing structure-based, small-molecule selective kinase inhibitors for cancer, advancing ROS1-targeted NVL-520, ALK-targeted NVL-655, and discovery-stage programs.
Focus Areas
Recent Investors
Valuation as of 01/27/2021
Total Raised
Funding rounds
Investors
See the team members at Nuvalent.
